Skip to main content
PMC home page
Molecular Medicine logoLink to Molecular Medicine
. 1995 Sep;1(6):700–705.

A mutation unique in serine protease inhibitors (serpins) identified in a family with type II hereditary angioneurotic edema.

J G Ocejo-Vinyals 1, F Leyva-Cobián 1, J L Fernández-Luna 1
PMCID: PMC2229981  PMID: 8529136

Abstract

BACKGROUND: Hereditary angioneurotic edema (HANE) is an autosomal dominant disease due to genetic alterations at the C1 inhibitor gene. Mutations within the C1 inhibitor gene are responsible for the molecular defect in type II HANE. Most of the dysfunctional proteins result from mutations involving the Arg-444 (the P-1 site of the reactive center) or amino acids NH2-terminal to the reactive center. MATERIALS AND METHODS: We have studied a Spanish family with type II HANE by using polymerase chain reaction (PCR) to amplify the exon eight of the C1 inhibitor gene. The purified 338-bp PCR product was subcloned and transformed into competent cells. After overnight cultures, we extracted the cloning vector from the positive colonies and sequenced both strands of the PCR product from each patient and healthy members of the family. RESULTS: We show that affected individuals in this family have a missense mutation, changing an adenine to cytosine in the codon 445. This substitution changes threonine at the P-1' site of the reactive center to a proline. This mutation generates a new restriction site, recognized by Bsi YI. CONCLUSIONS: To our knowledge, this is the first molecular defect characterized in a Spanish family with type II HANE, and to date, this is the first reported mutation at the P-1' site of the reactive center in individuals with type II HANE. This new mutation located at the reactive center emphasizes once more time the enormous heterogeneity of this gene.

Full text

PDF
700

Images in this article

701FIG. 1
on p.701
703FIG. 2
on p.703
703FIG. 3
on p.703

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ariga T., Igarashi T., Ramesh N., Parad R., Cicardi M., Davis A. E., 3rd Type I C1 inhibitor deficiency with a small messenger RNA resulting from deletion of one exon. J Clin Invest. 1989 Jun;83(6):1888–1893. doi: 10.1172/JCI114095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aulak K. S., Cicardi M., Harrison R. A. Identification of a new P1 residue mutation (444Arg----Ser) in a dysfunctional C1 inhibitor protein contained in a type II hereditary angioedema plasma. FEBS Lett. 1990 Jun 18;266(1-2):13–16. doi: 10.1016/0014-5793(90)81494-9. [DOI] [PubMed] [Google Scholar]
  3. Bennett B., Croll A., Ferguson K., Booth N. A. Complexing of tissue plasminogen activator with PAI-1, alpha 2-macroglobulin, and C1-inhibitor: studies in patients with defibrination and a fibrinolytic state after electroshock or complicated labor. Blood. 1990 Feb 1;75(3):671–676. [PubMed] [Google Scholar]
  4. Bissler J. J., Cicardi M., Donaldson V. H., Gatenby P. A., Rosen F. S., Sheffer A. L., Davis A. E., 3rd A cluster of mutations within a short triplet repeat in the C1 inhibitor gene. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9622–9625. doi: 10.1073/pnas.91.20.9622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bock S. C., Skriver K., Nielsen E., Thøgersen H. C., Wiman B., Donaldson V. H., Eddy R. L., Marrinan J., Radziejewska E., Huber R. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry. 1986 Jul 29;25(15):4292–4301. doi: 10.1021/bi00363a018. [DOI] [PubMed] [Google Scholar]
  6. Booth N. A., Walker E., Maughan R., Bennett B. Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1. Blood. 1987 Jun;69(6):1600–1604. [PubMed] [Google Scholar]
  7. Carter P. E., Duponchel C., Tosi M., Fothergill J. E. Complete nucleotide sequence of the gene for human C1 inhibitor with an unusually high density of Alu elements. Eur J Biochem. 1991 Apr 23;197(2):301–308. doi: 10.1111/j.1432-1033.1991.tb15911.x. [DOI] [PubMed] [Google Scholar]
  8. Cooper D. N., Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet. 1988 Feb;78(2):151–155. doi: 10.1007/BF00278187. [DOI] [PubMed] [Google Scholar]
  9. DONALDSON V. H., EVANS R. R. A BIOCHEMICAL ABNORMALITY IN HEREDIATRY ANGIONEUROTIC EDEMA: ABSENCE OF SERUM INHIBITOR OF C' 1-ESTERASE. Am J Med. 1963 Jul;35:37–44. doi: 10.1016/0002-9343(63)90162-1. [DOI] [PubMed] [Google Scholar]
  10. DONALDSON V. H. Studies on the activation of a serum esterase with ether and its relationship to C'l-esterase. J Clin Invest. 1961 Apr;40:673–683. doi: 10.1172/JCI104300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Davis A. E., 3rd C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol. 1988;6:595–628. doi: 10.1146/annurev.iy.06.040188.003115. [DOI] [PubMed] [Google Scholar]
  12. Davis A. E., 3rd, Whitehead A. S., Harrison R. A., Dauphinais A., Bruns G. A., Cicardi M., Rosen F. S. Human inhibitor of the first component of complement, C1: characterization of cDNA clones and localization of the gene to chromosome 11. Proc Natl Acad Sci U S A. 1986 May;83(10):3161–3165. doi: 10.1073/pnas.83.10.3161. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Donaldson V. H., Bissler J. J. C1- inhibitors and their genes: an update. J Lab Clin Med. 1992 Apr;119(4):330–333. [PubMed] [Google Scholar]
  14. Donaldson V. H. C1-inhibitor and its genetic alterations in hereditary angioneurotic edema. Int Rev Immunol. 1993;10(1):1–16. doi: 10.3109/08830189309051168. [DOI] [PubMed] [Google Scholar]
  15. Forbes C. D., Pensky J., Ratnoff O. D. Inhibition of activated Hageman factor and activated plasma thromboplastin antecedent by purified serum C1 inactivator. J Lab Clin Med. 1970 Nov;76(5):809–815. [PubMed] [Google Scholar]
  16. Frangi D., Aulak K. S., Cicardi M., Harrison R. A., Davis A. E., 3rd A dysfunctional C1 inhibitor protein with a new reactive center mutation (Arg-444-->Leu). FEBS Lett. 1992 Apr 13;301(1):34–36. doi: 10.1016/0014-5793(92)80204-t. [DOI] [PubMed] [Google Scholar]
  17. Frangi D., Cicardi M., Sica A., Colotta F., Agostoni A., Davis A. E., 3rd Nonsense mutations affect C1 inhibitor messenger RNA levels in patients with type I hereditary angioneurotic edema. J Clin Invest. 1991 Sep;88(3):755–759. doi: 10.1172/JCI115373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Huber R., Carrell R. W. Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry. 1989 Nov 14;28(23):8951–8966. doi: 10.1021/bi00449a001. [DOI] [PubMed] [Google Scholar]
  19. Levy N. J., Ramesh N., Cicardi M., Harrison R. A., Davis A. E., 3rd Type II hereditary angioneurotic edema that may result from a single nucleotide change in the codon for alanine-436 in the C1 inhibitor gene. Proc Natl Acad Sci U S A. 1990 Jan;87(1):265–268. doi: 10.1073/pnas.87.1.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Parad R. B., Kramer J., Strunk R. C., Rosen F. S., Davis A. E., 3rd Dysfunctional C1 inhibitor Ta: deletion of Lys-251 results in acquisition of an N-glycosylation site. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6786–6790. doi: 10.1073/pnas.87.17.6786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. ROSEN F. S., PENSKY J., DONALDSON V., CHARACHE P. HEREDITARY ANGIONEUROTIC EDEMA: TWO GENETIC VARIANTS. Science. 1965 May 14;148(3672):957–958. doi: 10.1126/science.148.3672.957. [DOI] [PubMed] [Google Scholar]
  22. Ratnoff O. D., Pensky J., Ogston D., Naff G. B. The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor. J Exp Med. 1969 Feb 1;129(2):315–331. doi: 10.1084/jem.129.2.315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rosen F. S., Alper C. A., Pensky J., Klemperer M. R., Donaldson V. H. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest. 1971 Oct;50(10):2143–2149. doi: 10.1172/JCI106708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Salvesen G. S., Catanese J. J., Kress L. F., Travis J. Primary structure of the reactive site of human C1-inhibitor. J Biol Chem. 1985 Feb 25;260(4):2432–2436. [PubMed] [Google Scholar]
  25. Siddique Z., McPhaden A. R., Whaley K. C1-inhibitor gene nucleotide insertion causes type II hereditary angio-oedema. Hum Genet. 1993 Sep;92(2):189–190. doi: 10.1007/BF00219690. [DOI] [PubMed] [Google Scholar]
  26. Skriver K., Radziejewska E., Silbermann J. A., Donaldson V. H., Bock S. C. CpG mutations in the reactive site of human C1 inhibitor. J Biol Chem. 1989 Feb 25;264(6):3066–3071. [PubMed] [Google Scholar]
  27. Stoppa-Lyonnet D., Carter P. E., Meo T., Tosi M. Clusters of intragenic Alu repeats predispose the human C1 inhibitor locus to deleterious rearrangements. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1551–1555. doi: 10.1073/pnas.87.4.1551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Stoppa-Lyonnet D., Duponchel C., Meo T., Laurent J., Carter P. E., Arala-Chaves M., Cohen J. H., Dewald G., Goetz J., Hauptmann G. Recombinational biases in the rearranged C1-inhibitor genes of hereditary angioedema patients. Am J Hum Genet. 1991 Nov;49(5):1055–1062. [PMC free article] [PubMed] [Google Scholar]
  29. Travis J., Salvesen G. S. Human plasma proteinase inhibitors. Annu Rev Biochem. 1983;52:655–709. doi: 10.1146/annurev.bi.52.070183.003255. [DOI] [PubMed] [Google Scholar]
  30. Ziccardi R. J. A new role for C-1-inhibitor in homeostasis: control of activation of the first component of human complement. J Immunol. 1982 Jun;128(6):2505–2508. [PubMed] [Google Scholar]
  31. Ziccardi R. J. Spontaneous activation of the first component of human complement (C1) by an intramolecular autocatalytic mechanism. J Immunol. 1982 Jun;128(6):2500–2504. [PubMed] [Google Scholar]

Articles from Molecular Medicine are provided here courtesy of The Feinstein Institute for Medical Research at North Shore LIJ

RESOURCES